Events 03/10/25 AMED 10th Anniversary Symposium – retrospective and prospective –

The Japan Agency for Medical Research and Development（AMED） was established in 2015 as a funding agency that has a central role in promoting research and development in the medical field and improving the research environment in Japan, under the national “Healthcare and Medical Strategy.” AMED has worked on building and enhancing the management function of research and development management to maximize our work .

To commemorate this 10th anniversary, we are pleased to hold the symposium, reviewing our work through keynote lectures and discussions with experts, and sharing the future direction of research and development to the public and stakeholders. We look forward to your participation.

Hitotsubashi Hall
National Center of Sciences Building 2F,2-1-2 Hitotsubashi,Chiyoda-ku,Tokyo

Tokyo Metoro Hanzomon Line/Toei Mita Line/Toei Shinjuku Line “Jinbocho” Exit A9
Tokyo Metoro Tozai Line “Takebashi” Exit 1b
3-5minutes walk from the stations

• Access

Public, healthcare professionals, researchers, pharmaceutical industry personnel, government officials, etc.

Admission fee is free

General

• Registration Form

Press

• Registration Form

Japan Agency for Medical Research and Development (AMED)

Supported by

Cabinet Office, Children and Families Agency, Ministry of Internal Affairs and Communications, Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labor and Welfare, Ministry of Economy, Trade and Industry
(To be confirmed)

Lunch venue for bring in and lunch spot near Hitotsubashi Hall.

Lunch box is NOT prepared for this symposium. If you would like to bring your own lunch, you can use the lunch venue, but as the number of people allowed is limited, we recommend using nearby restaurants. Please see below for details.

Program

※Programs are subject to change.

Presenters

Speech by President of AMED

President, Japan Agency for Medical Research and Development (AMED) Dr. MISHIMA Yoshinao ―Profile― 1973　Graduated from the Department of Metallurgy, Faculty of Engineering,Tokyo Institute of Technology. 1975　Completed Master's course in Metallurgy, Graduate School of Science and Engineering, Tokyo Institute of Technology. 1979　Completed Doctoral course in Materials Science, Graduate School, University of California, Berkeley. 1981　Assistant Professor, Precision Engineering Laboratory, Tokyo Institute of Technology. 1989　Associate Professor, Tokyo Institute of Technology. 1997　Professor, Department of Materials Physics, Graduate School of Science and Engineering, Tokyo Institute of Technology. 2011　Executive Vice President (Education and International Affairs), Tokyo Institute of Technology. 2012　President, Tokyo Institute of Technology. (until March 2018) 2019　Director, Technology Strategy Research Center, New Energy and Industrial Technology Development Organization (NEDO). (April 2019 to March 2020) 2020　Second Term of Strategic Innovation Promotion Program (SIP) "Materials Revolution through Integrated Materials Development".

Keynote Speech

The University of Tokyo.   Visiting Professor, The University of Tokyo.   Former Chairman, The Expert Study Panel on Promotion of Healthcare Policy, Headquarters of Healthcare Policy.   Former Executive Director, RIKEN.   Former Program Director (PD) of the Project for Basic Medical Research, AMED.   Former Program Supervisor(PS) of P-PROMOTE, AMED. Prof MIYAZONO Kohei ―Profile― 1981　M.D. (Faculty of Medicine, The University of Tokyo.) 1986　Assistant Member and Associate Member, Ludwig Institute for Cancer Research, Uppsala, Sweden. (until 1995) 1988　Assistant Professor, Third Department of Internal Medicine, The University of Tokyo. 1995　Member and Chief, Department of Biochemistry, The Cancer Institute, Japanese Foundation for Cancer Research. 2000　Professor and Chair, Department of Molecular Pathology, Graduate School of Medicine, The University of Tokyo. 2011　Dean, Graduate School of Medicine, The University of Tokyo. (until 2019) 2017　Member of the Japan Academy. 2019　Executive Vice President, The University of Tokyo. 2020　Program Director (PD) of Project for Basic Medical Research, AMED. 2021　Distinguished University Professor, The University of Tokyo. 2022　Executive Director, RIKEN/Special University Professor Emeritus, The University of Tokyo. Team Leader, RIKEN Center for Integrative Medical Sciences, Laboratory for Cancer Invasion and Metastasis.

Deputy Director, The U.S. National Institutes of Health Dr. Tara A. Schwetz ―Profile― COMING SOON

Deputy Chief Medical Officer, UK Department of Health and Social Care Prof Thomas Waite ―Profile― 2006　Graduate in Medicine (MB BCh), University of Cardiff; holds subsequent postgraduate qualifications in public health, medical toxicology, and medical education. 2015　Graduate of the European Programme for Interventional Epidemiology Training. (EPIET) 2016　Helped establish the UK Public Health Rapid Support Team at Public Health England. 2017～Held various leadership roles in Public Health England, including the Extreme 2020　Event Health Protection team, NIS Global Public Health team, and Director of the Field Epidemiology Training Programme. 2020～During the COVID-19 pandemic, he contributed to the creation of the Joint 2021　Biosecurity Centre (JBC) and later became its Director of Health Analysis. 2021　present: Deputy Chief Medical Officer for England.

Deputy Director-General, European Commission Ms. Signe Ratso ―Profile― 1983　English philology Tartu University in Estonia. 1993　International trade and economics Tartu University in Estonia. 1994～Deputy Secretary General at the Ministry of Economic Affairs and Communications 2005　of the Republic of Estonia. 2006　Senior management positions in DG TRADE. 2018　Oversees some of the priority areas of the Commission in DG R&I such as the Human Frontier Science Program. 2024　Acting Director of Directorate A “ERA & Innovation”, Deputy Director-General and a member of the Management Board of the Directorate-General for Research and Innovation of the European Commission.

Chief Scientist, World Health Organization Sir Jeremy Farrar ―Profile― 1996～Trained in neurology and infectious diseases in London, Edinburgh,  2013　Oxford and in Melbourne. PhD in Immunology from the University of Oxford in partnership with the University of California in San Francisco and has over 600 publications. Director of the Clinical Research Unit Hospital for Tropical Diseases in Ho Chi Minh City Viet Nam. Fellow of the Academy of Medical Sciences UK, the National Academies USA, the European Molecular Biology Organization and a Fellow of The Royal Society. 2013　Director/CEO of the Wellcome Trust. 2023　Chief Scientist, WHO.

Panel Discussion 1
COVID-19: Our experiences and lessons learned in preparation for future pandemics.

[Moderator]

Director General, the Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA), AMED Dr. HAMAGUCHI Michinari ―Profile― 1980　Completed Doctoral Program at the Graduate School of Medicine, Nagoya University. 1985　Research Fellow at Rockefeller University, USA. 1993　Appointed Professor at Nagoya University School of Medicine. 2005　Appointed Dean of the Graduate School of Medicine and School of Medicine, Nagoya University. 2009　Appointed President of Nagoya University. 2015　Appointed President of the Japan Science and Technology Agency. (JST) 2022　Assumed current position（Director General, Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response. (SCARDA)

[Panelist]

Director, NEIDL at Boston University. Dr. Nancy J. Sullivan ―Profile― COMING SOON

Deputy Director-General, National Institute for Infectious Diseases Dr. MATANO Tetsuro ―Profile― 1985　School of Medicine, Faculty of Medicine, The University of Tokyo. (5 years in orthopedic clinical practice) 1994　Graduate School of Medicine, University of Tokyo. Researcher, AIDS Research Center, National Institute of Infectious Diseases. 1995　Visiting Fellow, NIAID, NIH. 1997　Senior Researcher, AIDS Research Center, National Institute of Infectious Diseases. 2001　Associate Professor, Graduate School of Medicine, University of Tokyo. 2006　Professor, Institute of Medical Science, University of Tokyo. 2010　Director, AIDS Research Center, National Institute of Infectious Diseases. 2022　Deputy Director-General, National Institute of Infectious Diseases.

CEO, Coalition for Epidemic Preparedness Innovations Dr. Richard J. Hatchett ―Profile― 1989　Bachelor of Arts (BA) summa cum laude, Vanderbilt University, College of Arts & Sciences. 1995　Doctor of Medicine (MD), Vanderbilt University, School of Medicine. 1995　Medical Internship and Residency, New York Hospital – Cornell Medical Center & Memorial Sloan-Kettering Cancer Center. 2003　Medical Oncology Fellowship, Duke University Medical Center. 2005　Associate Director, Radiation Countermeasures Research and Emergency Preparedness, NIAID, US NIH. Director for Bidefense, White House Homeland Security Council. 2009　Director for Medical Preparedness Policy, White House National Security Staff. 2011　Acting Director; Chief Medical Officer & Deputy Director, BARDA. 2017　Chief Executive Officer, Coalition for Epidemic Preparedness Innovations. (CEPI)

Panel Discussion 2
Getting inside scoop on Drug Discovery Ecosystem

[Moderator]

Representative Director, President and COO, CMIC HOLDINGS Co., Ltd. Ms. OISHI Keiko ―Profile― 1982　M.D. Biological Sciences (Graduate School of Science, The University of Tokyo). 1982　Nikkei McGraw-Hill, Inc. 1989　Genentech Japan, Inc. 1996　Manager of the Strategy Development Department, CMIC Co., Ltd. 2000　Director, CMIC Co., Ltd. 2013　Executive Vice President, CMIC Co., Ltd. 2018　Representative Director, President and COO, CMIC HOLDINGS Co., Ltd.

[Panelist]

Representative Director, President and CEO, ARC Therapies Inc. Dr. SUZUKI Rami ―Profile― 1999　Ph.D. in medicine from University College London Subsequent postdoctoral research at Imperial College. 2001　Venture capitalist of European Life Sciences, ITX Corporation Corporate Venture Capital. 2004　Corporate officer in charge of business development, Eisai Co., Ltd. 2017　Head of Business Development and division head of Medical Affair, Janssen Pharma K.K. 2020　CEO and Representative Director, Ferring Pharma KK. 2021　President and Representative Director, Moderna Japan. 2024　Representative Director and CEO, ARC Therapies Inc.

Board Director, CEO, Cyfuse Biomedical K.K. Ms. AKIEDA Shizuka ―Profile― 2004　Regenerative medicine and Gene therapy Projects at Kyushu University Hospital. 2010　Cyfuse as a startup member, involved in NEDO projects and others as principal researchers and involved in biomedical venture business as Head of R＆D Division leading number of projects internally and collaboratively. 2017　Received the Japan Science and Technology Agency President's Award at the University-Originated Startup Award Received the Science Council of Japan President's Award at Industry-Academia-Government Collaboration Honorary Award. 2019　Received the Small and Medium Enterprise Agency Secretary Award in JAPAN VENTURE AWARDS. 2022　The company was listed on the Tokyo Stock Exchange Growth Market. As a newly listed startup, it is committed to creating markets and industries in advanced medical fields through the development of Japan-originated and world-first products, contributing to society globally with Japan Quality manufacturing. Served as the director of the Japan Bioindustry Association and a member of the International Committee of the Japanese Society for Regenerative Medicine.

Senior Advisor, ARCH Venture Partners Dr. YOSHIKAWA Mayu ―Profile― 2014　Earned a Ph.D. in Life Sciences from the Graduate School of Frontier Sciences, University of Tokyo. Joined McKinsey ＆ Company. 2016　Joined a Japanese venture capital firm, leading bio investments and acceleration programs. 2023　Became a Senior Advisor at ARCH Venture Partners, focusing on company creation and business development leveraging Japanese academic technologies. Concurrently involved in the management of two biotech startups in Japan and the US.

Principal, The University of Tokyo Edge Capital Partners Co., Ltd. Ms. SHIOHARA Azusa ―Profile― 2013　Bachelor of Pharmacy, The University of Tokyo. 2015　MSc in Pharmaceutical Sciences, The University of Tokyo. Joined Arthur D. Little Japan. 2019　Manager, Arthur D. Little Japan. 2021　MBA, London Business School. Joined The University of Tokyo Edge Capital Partners Co., Ltd. 2023　Principal, The University of Tokyo Edge Capital Partners Co., Ltd.

Back to Programs

Contact

Secretariat of AMED 10th Anniversary Symposium
Tel：+81-(0)50-1748-7112
Business Hour: 10:00 - 17:00（Weekdays except Japanese holiday）
E-mail：amed-unei“AT”his-world.com
※*Please change "AT" to @ in the above e-mail address.